Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer
- 197 Downloads
How the interval between surgery and S-1 adjuvant chemotherapy (ACT), and S-1 relative dose intensity (RDI) affect prognosis in patients with stage II/III gastric cancer who undergo gastrectomy with D2 lymph node dissection followed by S-1 ACT is unclear.
We enrolled 95 patients with histopathologically confirmed gastric adenocarcinoma treated with gastrectomy with D2 dissection, followed by S-1 ACT.
Per ROC analysis, we used 32 days as the optimal cut-off interval to divide patients into the delayed group (started ACT ≥ 32 days) and the non-delayed group ( < 32 days). Their 5-year overall survival (OS) rates differed significantly (delayed: 54.2%, non-delayed: 85.4%; P < 0.0001). Per ROC analysis of patients without recurrence within 1 year post-surgery, patients were divided into the high RDI (RDIHigh; ≥ 64.6%) and low RDI (RDILow; < 64.6%) groups. Their 5-year OS rates differed significantly (RDIHigh: 76.9%, RDILow: 63.7%; P = 0.012). In multivariate analysis, RDI and interval before starting ACT were independent prognostic indicators. Five- year OS rates by subgroups were RDIHigh/non-delayed: 84.0%, RDIHigh/delayed: 66.8%, RDILow/non-delayed: 100%, and RDILow/delayed: 48.2% (P < 0.0001).
Early initiation and sufficient RDI for S-1 ACT can improve the prognosis of patients with stage II/III gastric cancer.
KeywordsAdjuvant chemotherapy Gastric cancer Prognosis Recurrence S-1
We thank Marla Brunker, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were carried out in accordance with the ethical standards of the institutional research committee and the 1964 Helsinki Declaration and its later amendments or with comparable ethical standards.
- 2.Fitzmaurice C, Allen C, Barber RM et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3(4):524–548CrossRefGoogle Scholar
- 6.Japanese Gastric Cancer Association (2014) The Japanese Gastric Cancer Treatment Guidelines 2014 (version 4). Kanehara, TokyoGoogle Scholar
- 9.Japanese classification of gastric carcinoma: 3rd English edition (2011). Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 14 (2):101–112Google Scholar
- 11.Eggermont AM, Steller EP, Sugarbaker PH (1987) Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery 102(1):71–78Google Scholar